QNRX
Quoin Pharmaceuticals, Ltd.NASDAQHealthcare$7.02+15.84%ClosedMarket Cap: $4.1M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
233.71
DCF Value
$3,573.95
FCF Yield
-329.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-481.6%
ROA
-79.0%
ROIC
-0.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-15.79B | $-14,776.76 |
| FY 2025 | $0.00 | $-15.80B | $-14,796.26 |
| Q3 2025 | $0.00 | $-3.9M | $-6.71 |
| Q2 2025 | $0.00 | $-3.7M | $-6.28 |
Trading Activity
Insider Trades
View AllStonepine Capital Management, LLC10 percent owner:
SellTue Mar 31
Cooper Joseph Patrickdirector
SellFri Feb 06
Culverwell Anthony Jamesdirector
SellFri Feb 06
Myers Michaeldirector, officer: Chief Executive Officer
SellFri Feb 06
Carter Denise P.director, officer: Chief Operating Officer
SellFri Feb 06
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.82
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.